Beta-blockers in COPD: time for reappraisal

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Respiratory Journal

• Publication date

  2016-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/13993003.01847-2015PMID 27390282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure.

  2015cited by this paper
• Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis

  2015cited by this paper
• Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age.

  2015cited by this paper
• β-Blockers are associated with a reduction in COPD exacerbations

  2015cited by this paper
• β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature

  2015cited by this paper
• An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

  2015cited by this paper
• Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease

  2015cited by this paper
• β‐Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study

  2015cited by this paper
• Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.

  2015cited by this paper
• Multicentric study on the beta-blocker use and relation with exacerbations in COPD.

  2014cited by this paper
• Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality

  2014cited by this paper
• Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies

  2014influential reference
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Influence of β2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma.

  2014cited by this paper
• The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma.

  2014cited by this paper
• Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis.

  2014cited by this paper
• Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma.

  2013cited by this paper
• Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records

  2013cited by this paper
• Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease.

  2013cited by this paper
• Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

  2013cited by this paper
• Exercise Capacity and Ventilatory Response During Exercise in COPD Patients With and Without β Blockade

  2013cited by this paper
• Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).

  2013cited by this paper
• Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study.

  2013cited by this paper
• The clinical and economic burden of chronic obstructive pulmonary disease in the USA

  2013cited by this paper
• Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

  2013cited by this paper
• Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.

  2013cited by this paper
• Effects of intravenous and oral β-blockade in persistent asthmatics controlled on inhaled corticosteroids

  2013cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease

  2012cited by this paper
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• Beta-blocker use and COPD mortality: a systematic review and meta-analysis

  2012influential reference
• Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD

  2012cited by this paper
• The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD.

  2012influential reference
• β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

  2012cited by this paper
• Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease.

  2012cited by this paper
• Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists.

  2011cited by this paper
• Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.

  2011cited by this paper
• Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study

  2011cited by this paper
• Increased educational attainment and its effect on child mortality in 175 countries between 1970 and 2009: a systematic analysis.

  2010cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptors

  2010cited by this paper
• Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.

  2010cited by this paper
• Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation.

  2010cited by this paper
• Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.

  2010cited by this paper
• Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology

  2009cited by this paper
• Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure

  2009cited by this paper
• Think the impossible: beta-blockers for treating asthma.

  2009cited by this paper
• Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial

  2009cited by this paper
• Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model.

  2008cited by this paper
• Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.

  2008cited by this paper
• Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

  2008cited by this paper
• Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure.

  2008cited by this paper
• Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Chronic obstructive pulmonary disease and cardiovascular disease.

  2006cited by this paper
• Clinical Investigations: COPDDetrimental Effects of β-Blockers in COPD: A Concern for Nonselective β-Blockers

  2005cited by this paper
• Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

  2005cited by this paper
• The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors

  2005cited by this paper
• Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease.

  2005cited by this paper
• The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

  2005cited by this paper
• Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.

  2005cited by this paper
• β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome

  2005cited by this paper
• A comparison of the beta1-selectivity of three beta1-selective beta-blockers.

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.

  2003cited by this paper
• Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.

  2003cited by this paper
• A comparison of the β1‐selectivity of three β1‐selective β‐blockers

  2003cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma.

  2001cited by this paper
• Marked sympathetic activation in patients with chronic respiratory failure.

  2001cited by this paper
• Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease

  2001cited by this paper
• Modulation of neutrophil migration and superoxide anion release by metoprolol.

  2000cited by this paper
• Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study.

  2000cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• β Blockade after myocardial infarction: systematic review and meta regression analysis

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Beta‐blockers reduce the release and synthesis of endothelin‐1 in human endothelial cells

  1999cited by this paper
• beta Blockade after myocardial infarction: systematic review and meta regression analysis.

  1999cited by this paper
• Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects.

  1996cited by this paper
• Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers.

  1995cited by this paper
• Adverse effects of hypoxaemia on diastolic filling in humans.

  1995cited by this paper
• Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol.

  1995cited by this paper
• Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.

  1995cited by this paper
• Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects.

  1993cited by this paper
• Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

  1992cited by this paper
• A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

  1991cited by this paper
• Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease.

  1988cited by this paper

• Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network.

  2026cites this paper
• Penggunaan Β-Blockers Pada Pasien Gagal Jantung Fraksi Ejeksi Menurun

  2025cites this paper
• Off-Label Explorations: Beta Blockers Misuse among University Students in Jordan

  2025cites this paper
• Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis

  2024cites this paper
• Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.

  2024cites this paper
• ASSOCIATION OF BETA BLOCKER USE AND COPD MORTALITY: A SYSTEMATIC REVIEW

  2024cites this paper
• Systematic Estimation of Treatment Effect on Hospitalization Risk as a Drug Repurposing Screening Method.

  2023cites this paper
• Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

  2023cites this paper
• Neuroimmune Interactions in the Lung.

  2023cites this paper
• Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential

  2022cites this paper
• Beta-blockers Therapy after Myocardial Infarction: Which and for How Long is more Effective? A literature Review

  2022cites this paper
• Impact of COPD and asthma on in-hospital mortality and management of patients with heart failure in England and Wales: an observational analysis

  2022cites this paper
• Lung Function and the Risk of Exacerbation in the BLOCK COPD Trial.

  2022cites this paper
• Clinical heterogeneity of a population of patients admitted to the Emergency Department with a diagnosis of COPD-exacerbation: Relevance of cardiovascular comorbidities

  2021cites this paper
• Alteration of Relative Rates of Biodegradation and Regeneration of Cervical Spine Cartilage through the Restoration of Arterial Blood Flow Access to Rhomboid Fossa: A Hypothesis

  2021cites this paper
• [Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease].

  2021cites this paper
• Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers

  2021cites this paper
• The Correlation of Lung Function Parameters, Blood Pressure and Beta-Blocker Medication in a General Population

  2021cites this paper
• Reversed Biodegradation in Cervical Spine Cartilage: The Search for an Acceptable Way to Provide the Evidence for the Hypothesis

  2021cites this paper
• Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update

  2021cites this paper
• Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis.

  2021influential citation
• Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease

  2021cites this paper
• Endothelial dysfunction in patients with chronic obstructive pulmonary disease: some aspects of medicamental treatment (a literature review)

  2021cites this paper
• Comorbidities Associated With Chronic Obstructive Pulmonary Disease

  2021cites this paper
• A Novel Pleiotropic Effect of Beta-Blockers: Useful or Not?

  2020cites this paper
• Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) – Study protocol from a randomized controlled trial

  2020cites this paper
• Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension

  2020influential citation
• The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection

  2020cites this paper
• COMBORIDITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR DISEASES: GENERAL FACTORS, PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL SIGNIFICANCE

  2020cites this paper
• [Update on beta blockers in 2020].

  2020cites this paper
• Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study

  2020influential citation
• Сердечно-сосудистые заболевания и хроническая обструктивная болезнь легких: этиопатогенетическая взаимосвязь и клиническое значение (обзор литературы)

  2020cites this paper
• Mise au point sur les bêtabloquants en 2020

  2020cites this paper
• Does Metoprolol Influence the Risk of Exacerbation in a High-risk COPD Patient Population?

  2020cites this paper
• Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis

  2020cites this paper
• Role of β2-adrenergic receptors in chronic obstructive pulmonary disease.

  2020cites this paper
• Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly

  2020cites this paper
• The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review

  2020cites this paper
• Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study

  2020influential citation
• Cardiovascular diseases and chronic obstructive pulmonary disease: etiopathogenetic relationship and clinical signifi cance (literature review)

  2020cites this paper
• Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non–Small Cell Lung Cancer

  2019cites this paper
• Time-updated resting heart rate predicts mortality in patients with COPD

  2019cites this paper
• Herzinsuffizienz, COPD und Betablocker-Therapie

  2019cites this paper
• Accounting for time‐dependent treatment use when developing a prognostic model from observational data: A review of methods

  2019cites this paper
• Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge

  2019cites this paper
• COPD and Comorbidities: Relating Mechanisms and Treatment

  2019cites this paper
• The Heart–Lung Dilemma in COPD: A Tale of Two Cities

  2019cites this paper
• Acutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival.

  2019cites this paper
• Current Status of the Application of the Empowerment Theory in Patients with Chronic Obstructive Pulmonary Disease

  2019cites this paper
• The Heart-Lung Dilemma in COPD: A Tale of Two Cities.

  2019cites this paper
• JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　- Digest Version.

  2019cites this paper
• Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure.

  2019cites this paper
• Acute management of atrial fibrillation with rapid ventricular response.

  2019cites this paper
• Chronic obstructive pulmonary disease and myocardial infarction: when will we get our act together?

  2019cites this paper
• COPD and MI: when will we get our act together?

  2019cites this paper
• COPD Guidelines: A Review of the 2018 GOLD Report

  2018cites this paper
• Defining the relationship between COPD and CVD: what are the implications for clinical practice?

  2018cites this paper
• The role of beta-blockers in the management of chronic obstructive pulmonary disease

  2018cites this paper
• Manejo integral del paciente con exacerbación aguda de la enfermedad pulmonary

  2018cites this paper
• Evaluation of the protective effects of β‐blockers in the management of acute exacerbations of chronic obstructive pulmonary disease

  2018cites this paper
• Beta-Blockers in COPD: A Methodological Review of the Observational Studies

  2018cites this paper
• Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary

  2018cites this paper
• &bgr;‐Blockers in COPD: A Cohort Study From the TONADO Research Program

  2018cites this paper
• Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease

  2017influential citation
• Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.

  2017cites this paper
• Commencement of cardioselective beta‐blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease

  2017cites this paper
• Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD

  2017cites this paper
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

  2017cites this paper
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

  2017cites this paper
• COPD and bronchodilators: should the heart pay the bill for the lung?

  2017cites this paper
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report

  2017cites this paper
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

  2017cites this paper
• Beta-blockers and COPD: the show must go on

  2016cites this paper
• Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.

  2016cites this paper